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Abstract
Background: The dopaminergic neurodegeneration in the nigrostriatal pathway is a prominent neuropathological
feature of Parkinson’s disease (PD). Mutations in various genes have been linked to familial PD, and leucine-rich
repeat kinase 2 (LRRK2) gene is one of them. LRRK2 is a large complex protein, belonging to the ROCO family of
proteins. Recent studies suggest that the level of LRRK2 protein is one of the contributing factors to PD
pathogenesis. However, it remains elusive how LRRK2 is regulated at the transcriptional and translational level.
Results: In this study, we cloned a 1738 bp 5’-flanking region of the human LRRK2 gene. The transcriptional start
site (TSS) was located to 135 bp upstream of translational start site and the fragment −118 to +133 bp had the
minimum promoter activity required for transcription. There were two functional Sp1- responsive elements on the
human LRRK2 gene promoter revealed by electrophoretic mobility shift assay (EMSA). Sp1 overexpression promoted
LRRK2 transcription and translation in the cellular model. On the contrary, application of mithramycin A inhibited
LRRK2 transcriptional and translational activities.
Conclusion: This is the first study indicating that Sp1 signaling plays an important role in the regulation of human
LRRK2 gene expression. It suggests that controlling LRRK2 level by manipulating Sp1 signaling may be beneficial to
attenuate PD-related neuropathology.
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder, affecting 1–2 % of individ-
uals older than 65 years of age and 4–5 % of people who
are 85-year-old [1–3]. Its clinical manifestations are
characterized by bradykinesia, resting tremor, muscular
rigidity and postural instability [4]. Pathologically, there
are two prominent features seen in PD patients. One is
severe and relatively selective dopaminergic neurodegen-
eration in the nigrostriatal pathway, which underlies the
deficits in the motor systems [5, 6]. The other is
cytoplasmic Lewy bodies (LBs), which primarily consist
of aggregated alpha-synuclein [7]. Although tremendous
efforts have been put into discovering the effective ther-
apies, most of the treatments today are only palliative
instead of modifying disease progression. Over the past
years, several genes with mutations have been identified
in the familial PD cases, including alpha-synuclein (SNCA)
[8, 9], leucine-rich repeat kinase 2 (LRRK2) [2, 3], Parkin
[10], PTEN induced putative kinase 1 (PINK1) [11], DJ-1
[12], ATP13A2 or PARK9 [13], and VPS35 [14, 15].
Among these key players, mutations in the LRRK2
contribute to the most frequent cause of familial PD,
and LRRK2 variants are also implicated to increase
risk factors in the sporadic cases [16, 17]. Addition-
ally, clinical features of LRRK2-associated PD patients
are indistinguishable from the idiopathic cases, and
most LRRK2 mutation carriers are positive for alpha-
synuclein LBs [18]. Moreover, multiple lines of evi-
dence support that LRRK2 interacts with other key
molecules in the PD pathogenesis, including SNCA,
Parkin, DJ-1 and PINK [19–21].
LRRK2 gene contains 51 exons and encodes a large
286kD complex protein of 2527 amino acids. It belongs
to the ROCO family of proteins, characterized by a cata-
lytic Ras of complex proteins (ROC) GTPase domain, a
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C-terminal of ROC (COR) domain and a kinase domain,
which phosphorylates serine/threonine residues. This
central tri-domain is flanked by various potential
protein-protein interaction domains, including armadillo
(ARM), ankyrin (ANK), leucine-rich and WD40 repeats
[3, 22]. LRRK2 mRNA is widely expressed throughout
the brain and other organs, including kidney, heart, lung,
and liver [23]. In the brain, it is relatively high in the
dopaminoceptive regions instead of dopaminergic neu-
rons [24, 25].
LRRK2, also known as PARK8, was first discovered in
autosomal-dominant, late-onset parkinsonism by genetic
linkage analysis in 2002, and two years later, LRRK2
gene was cloned and its related mutations were reported
[2, 3, 26]. Extensive works have been done to explore
the pathophysiological role of LRRK2. Several pieces of
data suggest that LRRK2 is involved in regulating neurite
growth and cytoskeleton dynamics [27–29], maintaining
functions of autophagy and lysosome [30–34], and
modifying protein translation [35, 36] and vesicle traf-
ficking [37–39]. There are over 75 substitutions have
been found in LRRK2, and seven missense mutations
(G2019S, I2020T, N1437H, R1441G/C/H and Y1699C) are
pathogenic, all of which are concentrated in the central
catalytic domains, suggesting an essential role of GTPase
and kinase domains in the PD pathogenesis [40, 41].
Carboxyl terminus of HSP70-interacting protein
(CHIP) was shown to interact with LRRK2 and be in-
volved in regulating steady-state level of LRRK2 through
ubiquitin proteasomal degradation pathway. Knockdown
of CHIP was capable of exacerbating wildtype (WT) and
mutant LRRK2-induced cell toxicity [42]. A more recent
study implicated that the level of mutant LRRK2 was
more predicative than kinase activity for its pathogenic
effect and formation of inclusion bodies in neurons, sug-
gesting manipulation of cellular level of LRRK2 is an-
other option for treating LRRK2-associated PD [43].
Dysregulation of transcription was implicated in Alz-
heimer’s disease (AD), Huntington’s disease (HD) and
PD [44–52]. A study found that LRRK2 mRNA was
decreased in PD patients with comparison to control
subjects [53]. However, it is still unknown that how
LRRK2 is regulated at the transcriptional and transla-
tional level.
In this study we functionally analyzed human LRRK2
gene transcription. We first identified its transcription
start site (TSS) and cloned its 1738 bp promoter region.
There were multiple putative transcription factor-binding
sites for various transcription factors, including Sp1,
GATA1/2, c-Jun, HNF-3α, and NF-AT1. Furthermore, the
transcription factor Sp1 was shown to promote human
LRRK2 gene promoter activity and gene expression,
whereas its inhibitor, mithramycin A (MTM), reduced the
promoter activity and gene expression. This is the first
study to examine the role of Sp1 signaling in regulating
LRRK2 gene expression.
Results
Cloning the human LRRK2 gene promoter and mapping
its transcriptional start site
To define the region of LRRK2 gene promoter, total
RNA was extracted from HEK293 cell and 5’-rapid amp-
lification of cDNA ends (RACE) assay was applied to
identify the transcriptional start site of human LRRK2
gene. After amplifying the full length of LRRK2 cDNA,
two pairs of primers were used to perform nested poly-
merase chain reaction (PCR). An ~300 bp band was
yielded after inner PCR on 1.5 % agarose gel and the se-
quencing results indicated that the TSS was located
135 bp upstream of translational start site (ATG) (Fig. 1a,
b). The transcriptional start site began with guanine and
was designated as +1. To study the human LRRK2 gene
promoter, a 1738 bp 5’-flanking region of human LRRK2
gene was cloned from HEK293 cell gDNA and the
fragment was sequenced. A computational transcription
factor search (PROMO, online tool) for 5’-flanking re-
gion of the human LRRK2 gene revealed that the human
LRRK2 promoter contains several putative regulatory
elements, including Sp1, GATA1/2, c-Jun, HNF-3α, and
NF-AT1 (Fig. 1c).
Functional analyses of the human LRRK2 gene promoter
To investigate the activity of human LRRK2 gene pro-
moter, ten deletion fragments of its 5’-flanking region
were cloned into pGL3-Basic vector (Fig. 2a). The con-
struction of plasmids was verified by enzyme digestion
(Fig. 2b). This vector lacks eukaryotic promoter and en-
hancer, but contains a firefly luciferase reporter gene.
The expression of luciferase gene is driven by the cor-
rectly inserted promoter upstream of it. Constructed
plasmids were transfected into cells and the inserted
promoters’ activities were evaluated by the biolumines-
cent measurement of luciferase protein. The promoter
activity of pLRRK2-A plasmid covering from −1738 bp
to +133 bp was 8.27 ± 0.35 RLU, significantly higher than
pGL3-Basic (P < 0.0001, Fig. 2c), indicating that this frag-
ment worked as a functional promoter. To validate lucif-
erase assay, four plasmids lacking TSS in its promoter
region, including pLRRK2-B, pLRRK2-D, pLRRK2-H
and pLRRK2-I, were served as experimental negative
controls. As expectedly, all of four plasmids did not have
promoter activities when comparing with pGL3-Basic
(p > 0.05). A 944 bp deletion from pLRRK2-A to con-
struct pLRRK2-C significantly increased promoter activ-
ities to 11.25 ± 0.38 RLU (p < 0.0001). Promoter activity
of pLRRK2-E, containing a fragment −495 to +133 bp,
was 7.70 ± 0.29 RLU, significantly weaker than pLRRK2-C
(p < 0.0001). A further deletion from −495 bp (pLRRK2-E)
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to −413 bp (pLRRK2-F) drastically increased promoter ac-
tivity to 15.52 ± 0.23 RLU (p < 0.0001) and a deletion of
295 bp from pLRRK2-F to create pLRRK2-G significantly
lowered promoter activity to 9.89 ± 0.56 RLU (p < 0.0001).
Importantly, when the fragment from −118 to −34 bp was
deleted from pLRRK2-G to generate pLRRK2-J, promoter
activity became negligible (0.78 ± 0.02 RLU). These data
suggest that the fragment −118 to +133 bp has the
minimum promoter activity required for transcription.
Additionally, promoter regions from −1738 to −794 bp
and −495 to −413 bp have negatively regulatory cis-act-
ing elements and promoter region from −794 to
−495 bp and −413 to −118 bp have upregulatory cis-
acting elements.
The human LRRK2 gene contains Sp1 binding sites
Computational transcription factor search (PROMO, on-
line tool) the human LRRK2 gene revealed three putative
Fig. 1 Identification of TSS and sequence features of the human LRRK2 gene promoter. a Smarter RACE cDNA amplification kit was used to
amplify full-length cDNA from HEK293 cells. Nested PCR was performed and the product was resolved on 1.5 % agarose gel. b TSS was located
by sequencing PCR product. The first base pair after SMARTer oligonucleotide is the TSS, which is indicated by arrow in Figure. c Sequence of the
human LRRK2 promoter from -1865 bp to + 213 bp of the TSS (+1) is illustrated here. The putative transcription factor binding sites are underlined
by computational search
Wang and Song Molecular Brain  (2016) 9:33 Page 3 of 13
sp1 binding sites in its promoter region, including −537
to −529 bp, −263 to −254 bp and −51 to −43 bp (Fig. 1c).
To examine the effect of Sp1 on human LRRK2 gene
promoter, the promoter activities of pLRRK2-C, which
contained all three putative Sp1 binding sites, were mea-
sured in HEK293 cells cotransfected with Sp1 expression
plasmids. The promoter activities of pLRRK2-J with no
putative Sp1 binding sites were also examined to serve
as a negative control (Fig. 3a). The results showed that
the promoter activity of pLRRK2-C significantly in-
creased from 10.43 ± 0.68 RLU to 34.79 ± 2.01 RLU after
Sp1 overexpression (p < 0.001), but not for the promoter
activity of pLRRK2-J (p > 0.05), demonstrating that Sp1
upregulated LRRK2 gene promoter activity in HEK293
cells. To confirm the specificity of Sp1’s effect on LRRK2
promoter activity, Sp1 siRNA was used to knock down
all three isoforms for human Sp1, and a scrambled
siRNA serves as a negative control. The endogenous Sp1
expression was significantly decreased in the HEK293 by
the siRNA treatment cells (Fig. 4j). Knockdown of
endogenous Sp1 significantly reduced the promoter
activities of pLRRK2-C from 11.57 ± 0.46 RLU to 2.53 ±
0.01 RLU (p < 0.0001), but had no effect on plasmid
pLRRK2-J (p > 0.05) (Fig. 3b).
To determine whether all three putative Sp1 binding
sites were functional, EMSA was conducted to examine
the binding between Sp1 and these promoter regions in
vitro (Fig. 3c). Sp1 expression plasmid pCGN-Sp1 was
transfected into HEK293 cells followed by extracting
nuclear proteins from cell lysate. Double-stranded nucle-
otides containing the Sp1 consensus binding sequence
(attcgatcgGGGCGGGgcgagc) were synthesized and
labelled with IRD700 dye. Therefore, a free probe band
can be observed on DNA polyacrylamide gel electro-
phoresis (PAGE) gel as shown in the first lane in Fig. 3c.
A shifted band was visualized on DNA PAGE gel after
adding Sp1- enriched nuclear extract (Fig. 3c, Lane 2).
To ensure the specificity of this shifted band, WT oligo-
nucleotides, containing Sp1 consensus binding sequence
without labeling, and unlabeled mutant oligonucleotides
were added to EMSA system. As expectedly, unlabeled
WT oligonucleotides with 2- fold concentration of
labelled probe successfully competed shifted band
(Fig. 3c, Lane 3) and more excess of WT competitors
further decreased intensity of the shifted band (Fig. 3c,
Lane 4). On the contrary, mutant oligonucleotides with
2-fold and 20-fold concentration of labelled probe had
little competing effect (Fig. 3c, Lane 5 and 6).
Fig. 2 Functional deletion analyses of the human LRRK2 gene promoter. a Schematic illustration of human LRRK2 promoter constructs consisting
a serial deletion fragments, which were cloned into pGL3-Basic plasmid. The arrows represent the direction of transcription and the numbers
indicate the start and ending point of each construct with respect to TSS. b LRRK2 promoter constructs were verified by restriction enzyme
digestion and the digested products were resolved on 1.5 % agarose gel. The size of vector is 4.8 kb and the size of inserts ranges from 84 to
1871 bp, which was further confirmed by sequencing. c Plasmids with different LRRK2 promoter constructs were cotransfected with pCMV-Luc
into HEK293 cells. Cell lysates were harvested 24 h post-transfection, and the luciferase activity of pCMV-luc was used for normalizing transfection
efficiency. The RLU of pGL3-Basic (marked as N) was designated as 1. The values represent means ± SEM, n =3, *p < 0.001, by analysis of variance
(ANOVA) with Sidak’s multiple comparison test. Comparisons were made between all other columns and the pGL3-basic control column
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To test the functionality of three putative Sp1 bind-
ing sites located in the human LRRK2 gene promoter,
double-stranded oligonucleotides were used to com-
pete for the Sp1 consensus binding sequence. The oli-
gonucleotides containing the first Sp1 binding site
competed shifted band in a dosage-dependent manner
(Fig. 3c, Lane 7 and 8). Similarly, the oligonucleotides
containing the third Sp1 binding site also lowered the
intensity of shifted band (Fig. 3c, Lane 9 and 10).
However, the second Sp1 binding site did not show
obvious competitive effect (Fig. 3c, Lane 11 and 12).
Taken together, these data suggest that there are two
functional Sp1 binding sites in human LRRK2 gene
promoter and the binding between Sp1 and cis-acting
elements on human LRRK2 promoter upregulated its
promoter activities.
Sp1 upregulates the LRRK2 gene expression
To determine whether Sp1 regulates LRRK2 gene ex-
pression, endogenous LRRK2 mRNA levels were mea-
sured after transfecting either pCGN-Sp1 expression
plasmid or control vector into HEK293 cells. Sp1 over-
expression resulted in a significant increase of LRRK2
mRNA level by 83.1 ± 18.4 % compared with control de-
tected by reverse transcription (RT)-PCR (p < 0.05,
Fig. 4a, b). Next, a dopaminergic cell line MN9D was
used to confirm the effect. Similarly, the LRRK2 mRNA
level was elevated to 144.10 ± 2.28 % with Sp1
Fig. 3 Regulation of the human LRRK2 gene promoter by Sp1. a pGL3-Basic, pLRRK2-C and pLRRK2-J plasmids were cotransfected with either
vector or Sp1 expression plasmid into HEK293 cells. Cell harvesting and the measurement of luciferase activities were performed as mentioned
before. Sp1 overexpression significantly increased the promoter activity of pLRRK2-C but had no effect on pLRRK2-J nor pGL3-basic control. The
values represent means ± SEM. n =3, *p < 0.01 by two way ANOVA with Sidak’s multiple comparison test. b pGL3-Basic, pLRRK2-C and pLRRK2-J
plasmids were cotransfected with either negative control or Sp1 siRNA into HEK293 cells. Knockdown of Sp1 significantly decreased the promoter
activity of pLRRK2-C but had no effect on pLRRK2-J. The values represent means ± SEM. n =3, *p < 0.01 by two-way ANOVA with Sidak’s multiple
comparison test. c EMSA was performed as described in detail in Material and Methods. Sp1 consensus binding sequence was labelled by fluorescent
IR700 Dye. Lane1 is the labelled probe alone without nuclear protein extract. Incubation the probes with Sp1-enriched nuclear protein extracts formed
a shifted DNA-protein complex band (lane 2). Competition assays were conducted by adding various concentrations of molar excess of unlabeled
competitive oligonucleotides, including consensus Sp1 oligonucleotides (lane 3 and 4), mutant Sp1 consensus oligonucleotides (lane 5 and 6) and
putative Sp1-responsive elements in the human LRRK2 promoter (lane 7 to 12)
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overexpression in MN9D cells (p < 0.001, Fig. 4c, d). On
the contrary, inhibition of endogenous Sp1 protein by
siRNA led to significantly lower expression of LRRK2
mRNA in HEK293 cells (p < 0.01, Fig. 4e, f ).
Although Sp1 drastically enhanced endogenous LRRK2
mRNA expression, it is not necessary that Sp1 can
increase its protein level. Therefore, expression of en-
dogenous LRRK2 protein was detected by immunoblot-
ting after pCGN-Sp1 plasmid or control vector being
transfected into HEK293 cells. In consistent with mRNA
data, Sp1 significantly augmented LRRK2 protein level by
81.7 ± 6.21 % (p < 0.005, Fig. 4g, h). However, when Sp1
Fig. 4 Sp1 upregulates the LRRK2 gene expression. a-d Sp1 overexpression increased LRRK2 mRNA expression level. Sp1 expression plasmid was
transfected into HEK293 cells (a) or MN9D cells (c). Cell lysates were harvested 48 h after transfection and total RNA was isolated for RT-PCR. The
products of amplified LRRK2 and β-actin genes were analyzed on a 1.5 % agarose gel. Quantification was performed by ImageJ software and
endogenous LRRK2 mRNA level was normalized against β-actin. e HEK292 cells were transfected with scrambled siRNA or Sp1 siRNA, and
endogenous LRRK2 mRNA level was measured by RT-PCR after 48 h and analyzed on a 1.5 % agarose gel. g HEK293 cells were transfected as
mentioned before and cell lysates were harvested 48 h after transfection. Endogenous LRRK2 protein and overexpressed Sp1 were examined by
immunoblotting. i HEK293 cells were transfected with negative control siRNA or Sp1 siRNA. After 48 h, cell lysate was harvested for determining
LRRK2 and Sp1 protein level by immunoblotting. Quantification of the band intensity in (f), (h), and (j) was performed by ImageJ software. The
values in this figure represent means ± SEM. n =3, *p < 0.05, analyzed by Student’s t-test
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was overexpressed in MN9D cells, measurement of
LRRK2 protein level was failed as endogenous LRRK2
protein cannot be detected in this cell line by any anti-
bodies we tried (data not shown). Knockdown of endogen-
ous Sp1 significantly lowered LRRK2 protein level by
74.52 ± 9.09 % (p < 0.005, Fig. 4i, j). Overall, the data
suggested that Sp1 can not only promote LRRK2 gene
promoter activity and also facilitate its gene expression
both at transcriptional and translational level.
Mithramycin A (MTM) inhibits human LRRK2 promoter
activity and gene expression
To further validate Sp1’s effect on LRRK2 gene expres-
sion, MTM, a selective Sp1 inhibitor competing with
Sp1 to bind to a GC-rich DNA sequence [54], was used
to treat cells. After HEK293 cells were transfected with
pLRRK2-C or pLRRK2-J plasmids, MTM was applied to
cells for either 24 or 48 h. With MTM treatment
(125nM), the promoter activities of the pLRRK2-C plas-
mid, containing Sp1 binding sites, were significantly
reduced from 9.72 ± 0.22 RLU to 4.40 ± 0.16 RLU
after 24 h and further to 3.53 ± 0.08 RLU after 48 h
(p < 0.0001 for both 24 and 48 h). Neither pLRRK2-J
nor pGL3-Basic’s promoter activities was affected by
MTM treatment (p > 0.05, Fig. 5a). To further con-
firm the effect of MTM treatment, various concentra-
tions of MTM were applied to HEK293 cells, ranging
from 25nM to 125nM. After 24 h treatment, promoter ac-
tivities of pLRRK2-C plasmid were significantly downreg-
ulated from 9.35 ± 0.41 RLU to 3.53 ± 0.14 RLU in 25nM
MTM treatment, further decreased to 1.37 ± 0.09 RLU in
75nM, and 0.38 ± 0.02 RLU in 125nM, respectively
Fig. 5 MTM inhibits the LRRK2 gene expression. a pGL3-Basic, pLRRK2-C or pLRRK2-J was transfected into HEK293 cells. After 24 h, transfected
cells were treated with MTM at 125 nM or vehicle for 24 or 48 h. Luciferase activities were determined as mentioned before, and pCMV-Luc lucif-
erase activity was used for transfection efficiency normalization. b HEK293 cells were transfected with pGL3-Basic, pLRRK2-C or pLRRK2-J. The next
day, cells were exposed to MTM at 25, 75 and 125 nM for 24 h. Luciferase activities were measured. The values in (a) and (b) represent the mean
± SEM. n = 3, *p < 0.001 by two-way ANOVA with Sidak’s multiple comparison test. c HEK293 cells were treated with 125 nM MTM or vehicle for
24 h. The LRRK mRNA levels were determined by RT-PCR and normalized against the levels of β-actin. d Quantification of LRRK2 and β-actin
mRNA levels in HEK293 cell were completed by ImageJ software. e Cell lysates harvested from HEK293 cells treated with 125 nM MTM or vehicle
for 24 h were analyzed by immunoblotting with anti-LRRK2 antibody. β-actin was used as the internal control for protein loading. f Quantification
of LRRK2 and β-actin protein levels in HEK293 cell was completed by ImageJ software. g Dopaminergic MN9D cells were treated with 125 nM
MTM or vehicle for 24 h. The LRRK mRNA levels were determined by RT-PCR and normalized against the levels of β-actin. h LRRK2 and β-actin
mRNA level in MN9D cell was quantified by ImageJ software. The values in (d), (f) and (h) represent the mean ± SEM. n = 3, *p < 0.001 by
Student’s t-test
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(p < 0.0001 for 25, 75 and 125nM. Fig. 5b). These
data indicate that MTM treatment inhibits LRRK2
promoter activities in a time -dependent and dosage-
dependent manner.
To examine LRRK2 mRNA expression in MTM treat-
ment, HEK293 cells were administrated with 125nM
MTM for 24 h. RT-PCR results showed that endogenous
LRRK2 mRNA level was significantly downregulated to
63.43 ± 1.66 % (p < 0.0001, Fig. 5c, d). Endogenous LRRK2
protein expression was also detected in HEK293 cells after
125nM MTM treatment for 24 h. LRRK2 protein was re-
duced to 38.30 ± 2.18 % (p < 0.0001, Fig. 5e, f ). LRRK2
mRNA expression after MTM treatment was confirmed
in MN9D cells, which was significantly reduced to 52.44
± 2.07 % (p < 0.001, Fig. 5g, h). Consistent with Sp1’s effect
on LRRK2 gene, inhibition of Sp1’s activity by MTM is
sufficient to reduce LRRK2 promoter activity and gene
expression.
Discussion
LRRK2 is one of the key players in the pathogenesis of
PD, and its physiological and pathophysiological func-
tions are studied extensively. LRRK2 is widely expressed
with relative low expression in dopamine-producing area
[24]. LRRK2 mRNA was found to be increased in the
PD subjects and a study suggests that the level of mu-
tant LRRK2 is associated with its toxic effect in neurons
[43, 53]. However, the transcriptional and translational
regulation of LRRK2 gene is still not known. In this
study, we cloned and functionally characterized LRRK2
promoter. The transcription stat site of the human
LRRK2 promoter was identified and the minimal pro-
moter required for transcriptional initiation was located.
Two Sp1-responsive elements were mapped in its pro-
moter region and Sp1 was capable of promoting en-
dogenous LRRK2 mRNA and protein expression in the
cellular models. Contrarily, application of MTM reduced
LRRK2 gene expression.
LRRK2 is a complex protein, featuring a central ROC-
COR domain and a kinase domain. Its cellular functions
were revealed by various loss-of-function studies. It was
showed that deletion of LRRK2 in primary neurons re-
sulted in longer neurites and elevated branching, the
mechanisms of which were involved decreased phos-
phorylation of ezrin, radixin, and moesin (ERM) and fila-
mentous actin [27, 28]. Deficiency of LRK1, homolog of
the human LRRK2 in C. elegans, led to the disturbance
of polarized location of synapses, suggesting that LRRK2
plays a role in vesicle trafficking [55]. Additional data
emerging from LRRK2 knockout mice indicated that
they actually did not severely compromise dopaminergic
functions, including normal dopaminergic synthesis, re-
lease and storage [56]. However, the deficit was obvious
in kidney with striking degeneration. This observation
was confirmed by another study, and the abnormalities
in the study were also seen in lung, both of which was
caused by impaired autophagy-lysosomal pathway [34].
As most of the pathogenic mutations are concentrated
in the central tri-domain, LRRK2’s kinase and GTPase
activities have garnered significant attention [41]. Over-
expression of mutant LRRK2 resulted in cell death and
inclusion formation in neuronal cells and primary neu-
rons, and increased kinase activities were linked to the
underlying mechanisms, especially for LRRK2 G2019S
mutant with consistently findings of its elevated kinase
activities [19, 57–59]. LRRK2 mutants with reduced kin-
ase activities were correlated with decreased neuronal
toxicities and kinase-dead versions blocked inclusion
formation and attenuated cell death [57, 60]. However, it
is challenging to conclude that kinase activity is the
major culprit of cell toxicity, as kinase activities of other
LRRK2 mutants are controversial, sometimes no influ-
ence, and sometimes decreased [61]. Another candidate
for pathogenic effect of LRRK2 mutations is the GTPase
ROC domain. It is well established that LRRK is an au-
thentic GTPase and PD-associated mutations located in
the ROC domain (R1441G/C/H) and COR domain
(Y1699C) decrease the rate of GTP hydrolysis [62–66].
Multiple lines of evidence supported that both GTP
binding and GTP hydrolysis were required for kinase ac-
tivity, but kinase-dead mutant did not have impact on
GTP binding [67, 68]. Expression of GTPase domain
alone was sufficient to impair yeasts’ viability, but the
fragment only containing kinase domain produced much
less toxic effect. Moreover, the fragment containing the
complete central tri-domain was the most toxic one,
suggesting kinase domain may have a modulating effect
on GTPase activity [69]. Collectively, it remains unclear
that whether kinase activity or GTPase activity is the
readout of LRRK2’s pathogenic effect, but it is certain
that both of them play an essential role in regulating the
overall function of LRRK2.
Although LRRK2 has become a hot topic in the field
of PD-related studies, the features of human LRRK2 pro-
moter has not been studied in detail. A previous study
suggested that there were at least six TSSs, ranging from
48 to 120 bp upstream of the first Kozak sequence, for
LRRK2 promoter by using human brain cDNA [58]. Our
identified TSS was 15 bp further, possibly due to cell-
type or tissue-type specific effect [70]. In the human
LRRK2 promoter sequence we cloned, there were mul-
tiple putative binding sites for various transcription fac-
tors including Sp1, c-Jun, HNF-3α, GATA-1/2, and
NFAT1. Dysregulation of Sp1 was reported in various
neurodegenerative disorders. Sp1 mRNA and protein
level were increased in frontal cortex of AD brains, and
the same results were also found in frontal cortex and
hippocampus of AD model mouse [71]. It was
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discovered that huntingtin interacted with Sp1 and its
coactivator, TAFII130, by using the yeast two-hybrid
assay, and the interaction between Sp1 and TAFII130
was inhibited by mutant huntingtin in HD subjects [44].
Additionally, our lab determined that Sp1 was able to
regulate several AD- and HD- associated genes, includ-
ing BACE1, huntingtin and SNAP-25 [48, 72, 73].
Sp1 was one of the first transcription factors to be cloned
in the 1980s [74]. It was originally discovered as a transcrip-
tion activator for simian virus 40 (SV40) by binding to
multiple GC-boxes in its early promoter [75]. Sp1 is ubiqui-
tously expressed and involved in cell growth, cell differenti-
ation, embryogenesis, and preventing CpG islands from
methylation [76–78]. There are four major domains (A, B,
C and D), featuring by two classic zinc fingers located in
domain C for sequence-specific DNA binding and do-
main A and B at the N-terminal for transcription acti-
vation [79, 80]. As a classic transcription factor, Sp1
can bind to GC-box and GT/CACCC-box [81, 82]. Its
consensus binding sequence is (G/T)GGGCGG(G/
A)(G/A)(C/T) [82]. Our data show that in human
LRRK2 promoter, the first putative binding site has se-
quence of GGGCGGTGC, the second CGTCCGCCCG,
and the third GGGGCGGGGA. The first putative bind-
ing site has two mismatched base pairs, the second with
three mismatched base pairs, and the third with only one
mismatched base pair. In consistent with prediction, only
the first and the third were functional binding sites.
MTM, an anti-tumor and antibiotic drug, was dis-
covered to bind to GC-rich sequence with high affin-
ity [83]. It competitively binds to Sp1 consensus
binding site on the SV40 promoter, working as a site-
specific inhibitor for Sp1 [84]. As expectedly, applica-
tion of MTM resulted in significantly reduced LRRK2
promoter activity and gene expression. It was re-
ported that LRRK2 WT or G2019S transgenic mice
alone did not develop neuropathological features seen
in the SNCA A53T transgenic mice, including astro-
cytosis, microgliosis, and neurodegeneration. However,
SNCA A53T/LRRK2 WT double transgenic mice
displayed increased reactive astrocytosis, microgliosis
and neuronal death. Furthermore, the severity of neu-
rodegeneration in the double transgenic mice was as-
sociated with expression level of WT LRRK2 proteins,
suggesting an essential role of LRRK2 expression level
in promoting mutant SNCA-induced neuropathology
[85]. Therefore, decreasing the LRRK2 level by MTM
could be beneficial to alleviate the PD-related patho-
logical alterations, although the off-target effects of
Sp1 inhibition should be taken into consideration.
Further studies will be necessary to explore the effect
of manipulating Sp1 signaling, for example by appli-
cation of MTM, on LRRK2 WT or mutant-induced
toxicity in PD model mice.
Conclusions
In summary, we functionally analyzed human LRRK2
gene transcription, identified its TSS and cloned its
1738 bp promoter region. Furthermore, the transcription
factor Sp1 was shown to promote human LRRK2 gene
promoter activity and gene expression, whereas its in-
hibitor, MTM, reduced the promoter activity and gene
expression. This is the first study to demonstrate that




LRRK2 gene promoter fragments were amplified from
genomic DNA of human embryonic kidney (HEK) 293
cells by PCR and then cloned into pGL3-Basic expres-
sion vector (Promega) upstream of the luciferase re-
porter gene by restriction enzymes. Ten promoter
deletion plasmids for 5’ flanking region of human
LRRK2 gene were generated to cover from −1738 bp up-
stream to +133 bp downstream of TSS at guanine (+1).
The primers, including restriction enzyme sites, were
synthesized as follows: forward, 1) - 1738NheI: ctagcta
gcgaaacaacttagaaaataatacactg, 2) -794NheI: ctagctagcccc
aagtatcaggatcctgcc, 3) -495 BglII: cttagatctggagataggcggc,
4) -413Nhe: ctagctagcggtcgcggagggtggccggc, 5) -1
18XhoI: ccgctcgagtcgtttttgggcctgagt, and 6) -34XhoI: ccg
ctcgagtccttcctcataaacaggcg; reverse, 1) -794HindIII: ccca
agcttggcaggatcctgatacttggg, 2) -413HindIII: cccaagcttgc
cggccaccctccgcgacc, 3) -34HindIII: cccaagcttaggcagctccc
cgccccgcgt, 4) -4HindIII: cccaagcttgcgcccacgcccgcctgttta,
and 5) +133HindIII: cccaagctttggcacctgcttccaacccgccg.
Cell culture, transfection, luciferase reporter assay and
MTM treatment
HEK293 cells and MN9D cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
with 10 % fetal bovine serum, 1 mM of sodium pyruvate,
2 mM of L-glutamine, 50 units of penicillin and 50 μg of
streptomycin (Invitrogen). MN9D cells were cultured on
the plates coated with 10 μg/mL poly-D-lysine (Sigma).
All cells were maintained at 37 °C in an incubator con-
taining 5 % CO2. Sp1 expression plasmid was con-
structed by inserting Sp1 cDNA with hemagglutinin
(HA) tag into pCGN-expression plasmid under the con-
trol of the cytomegalovirus promoter [86]. Transfection
for overexpressing Sp1 in the HEK293 and MN9D cells
were performed with Lipofectamine 2000 (Invitrogen)
following manufacturer’s instruction.
For luciferase assays, cells were first cotransfected with
500 ng firefly luciferase plasmid (pGL3-Basic) with inser-
tion of various promoter fragments and 1 ng Renilla lucif-
erase plasmid pCMV-Luc which was used to normalize
for transfection efficiency. Cells were harvested by passive
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lysis buffer 24 h post-transfection. Firefly luciferase and
Renilla luciferase activities were measured by using the
dual-luciferase reporter assay system (Promega). The fire-
fly luciferase activities were normalized to Renilla lucifer-
ase activities and the promoter activities of various
deletion fragments were represented as relative luciferase
units (RLU) after normalizing to pGL3-Basic.
MTM (Sigma) was dissolved in 100 % methanol to
make a stock concentration of 250 mM. In dosage ex-
periments, HEK293 cells were treated with MTM at 0,
25, 75 and 125 nM for 24 h after 1 day transfection.
Similarly, for time course experiments, cells were treated
with MTM at 125 nM for 24 or 48 h. For RT-PCR and
immunoblotting, HEK293 and MN9D cells were treated
with 125 nM MTM for 24 h and then lysed for mRNA
and protein extraction.
5’- RACE assay
Total RNA was extracted from HEK293 cells by TRI re-
agent following the manufacturer’s instructions (Sigma).
5’- RACE was conducted using the Smarter RACE
cDNA amplification kit (Clotech) according to its proto-
col. In the reverse transcription, a patent SMARTScribe
Reverse Transcriptase was employed to generate full-
length first-strand cDNA and 3-5 bp residues were
added to its 3’ tailing. The SMARTer oligonucleotide
was annealed to the extended cDNA tail, and the oligo-
nucleotide was then worked as a template to amplify a
complete cDNA copy of the original RNA with the add-
itional SMARTer sequence at the end. The outer and
inner reverse primers were designed based on human
LRRK2 gene sequence, which were 5’-atcccagccatcatcca-
gacc and 5’- caggatttggaccagcgtttct, respectively. Nested
PCR was performed and PCR product was sequenced
to locate the TSS of the human LRRK2 gene, which
was the first base pair after SMARTer oligonucleotide
sequence.
EMSA
EMSA was performed as previously described [87].
HEK293 cells were transfected with pCGN-Sp1 expression
plasmid and lysed in a series of hypotonic buffers for nu-
clear protein extraction. Probe oligonucleotides were la-
belled with IR700 Dye (LI-COR Biosciences) and annealed
to produce double- stranded probes. The labelled probes
were incubated with or without nuclear extract at 22 °C
for 20 min in the EMSA binding buffer (4 % glycerol,
1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM
NaCl, 10 mM Tris-HCl (pH 7.4), and 50 μg/mL poly(dI-
dC)). For the competition assay, nuclear extract was first
incubated with 100 fmol (2 times excess) or 10 pmol (20
times excess) of unlabeled competition oligonucleotides
for 10 min followed by adding 50 fmol labelled probes.
The sequences of the oligonucleotides were: consensus
Sp1-forward: 5’-attcgatcggggcggggcgagc; consensus Sp1-
reverse: 5’-gctcgccccgccccgatcgaat; mutant Sp-1 forward:







reverse: 5’-cagctccccgccccgcgttg. The EMSA samples were
analyzed on 4 % non-denaturing polyacrylamide gels and
the gels were scanned using the Odyssey scanner (LI-COR
Biosciences) at a wavelength of 700 nm.
Sp1 knockdown
HEK293 cells were maintained at 30 % confluence for
transfection. For luciferase assay, the cells were cotrans-
fected either 50nM Silencer® Select negative control
siRNA or Sp1 siRNA (Thermofisher) with other pro-
moter plasmids by Lipofectamine 2000 (Invitrogen) fol-
lowing manufacturer’s instruction. Cells were analyzed
48 h after transfection. For RT-PCR and immunoblot-
ting, 50nM negative control siRNA or Sp1siRNA was
transfected into HEK293 cells by Lipofectamine 2000.
Cells were harvested 48 h after transfection. The sense
sequence of Sp1 siRNA is 5’-gcaacaugggaauuaugaatt and
the antisense sequence is 5’-uucauaauucccauguugctg.
RT-PCR
Total RNA was extracted from HEK293 or MN9D cells by
TRI reagent (Sigma). Thermoscript™ RT-PCR system (Invi-
trogen) was applied to amplify the first strand cDNA by
using 1.0 μg of total RNA as the template and then the
newly synthesized cDNA was further amplified by Taq
DNA polymerase. The specific primers for human LRRK2
gene were as follows: forward, 5’- gagcacgcctccaagttat, and
reverse, 5’- gtgattttacctgaagttag. This pair of primers was
used to amplify a 302 bp fragment of the human LRRK2
gene coding sequence in the HEK293 cells. Additionally,
the pair of primers for amplifying a 115 bp fragment of
mouse LRRK2 gene coding sequence in MN9D cells was as
follows: forward, 5’- aggagctgcccccttgaagaca, and reverse,
5’- tgtgccacaccctccccatgt. β-actin was used as an internal
control, and two pairs of gene specific primers for HEK293
and MN9D cells were: forward, 5’- ggacttcgagcaagagatgg,
reverse, 5’-gaagcatttgcggtggag, forward, 5’-gacaggatgcagaag-
gagat, and reverse, 5’-ttgctgatccacatctgctg, respectively. All
samples were analyzed on 1.5 % agarose gels.
Immunoblotting
HEK293 and MN9D cells were lysed in triton lysis buffer
(150 mM sodium chloride, 1.0 % Triton X-100, 50 mM
Tris-HCl (pH 8.0) and protease inhibitor cocktail (Roche),
followed by brief sonication. Protein concentration was
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measured by Bradford assay (Bio-rad) and 4x sodium
dodecyl sulfate (SDS) sample buffer was added to each
sample. Cell lysates were resolved by 6 % Tris-glycine
SDS-PAGE for detecting LRRK2 and 8 % Tris-glycine
SDS-PAGE was used to detect endogenous Sp1 and Sp1-
HA. Rabbit anti-LRRK2 monoclonal antibody MJFF C81-
8 (Abcam), rabbit anti-Sp1 polyclonal antibody PEP2
(Santa Cruz), mouse anti-β-actin monoclonal antibody
AC-15 (Sigma) and mouse anti-HA monoclonal antibody
12CA5 (Abcam) were used as primary antibodies. IRDye
680RD-labelled goat anti-rabbit antibodies and IRDye
800CW-labelled goat anti-mouse antibodies were applied
as secondary antibodies. The gels were scanned in the
Odyssey system (LI-COR Biosciences).
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